## CONGRESS-AT-A-GLANCE

<table>
<thead>
<tr>
<th>Time</th>
<th>Monday 4 Dec</th>
<th>Tuesday 5 Dec</th>
<th>Wednesday 6 Dec</th>
<th>Thursday 7 Dec</th>
<th>Friday 8 Dec</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00</td>
<td></td>
<td>Scientific Sessions</td>
<td>Scientific Sessions</td>
<td>Scientific Sessions</td>
<td>Scientific Sessions</td>
</tr>
<tr>
<td>09.00</td>
<td></td>
<td>coffee break</td>
<td>coffee break</td>
<td>coffee break</td>
<td>Scientific Sessions</td>
</tr>
<tr>
<td>10.00</td>
<td>Satellite Symposia</td>
<td>Scientific Sessions</td>
<td>Scientific Sessions</td>
<td>Scientific Sessions</td>
<td>Scientific Sessions</td>
</tr>
<tr>
<td>11.30</td>
<td></td>
<td>Poster Sessions</td>
<td>Poster Sessions</td>
<td>Poster Sessions</td>
<td>Lunch session</td>
</tr>
<tr>
<td>11.45</td>
<td>Satellite Symposia</td>
<td>Coffee break</td>
<td>Exhibition</td>
<td>Exhibition</td>
<td>Meet the speaker</td>
</tr>
<tr>
<td>12.30</td>
<td>IDF General Assembly</td>
<td>Poster Sessions</td>
<td>Poster Sessions</td>
<td>Exhibition</td>
<td></td>
</tr>
<tr>
<td>12.45</td>
<td>Satellite Symposia</td>
<td>Exhibition</td>
<td>Exhibition</td>
<td>Exhibition</td>
<td></td>
</tr>
<tr>
<td>13.15</td>
<td></td>
<td>Scientific Sessions</td>
<td>Scientific Sessions</td>
<td>Scientific Sessions</td>
<td>Scientific Sessions</td>
</tr>
<tr>
<td>14.30</td>
<td></td>
<td>coffee break</td>
<td>coffee break</td>
<td>coffee break</td>
<td>Scientific Sessions</td>
</tr>
<tr>
<td>14.45</td>
<td></td>
<td>Poster Sessions</td>
<td>Poster Sessions</td>
<td>Poster Sessions</td>
<td></td>
</tr>
<tr>
<td>15.15</td>
<td>Satellite Symposia</td>
<td>Scientific Sessions</td>
<td>Scientific Sessions</td>
<td>Scientific Sessions</td>
<td></td>
</tr>
<tr>
<td>15.30</td>
<td></td>
<td>Satellite Symposia</td>
<td>Satellite Symposia</td>
<td>Satellite Symposia</td>
<td>Satellite Symposia</td>
</tr>
<tr>
<td>16.45</td>
<td>Satellite Symposia</td>
<td>Satellite Symposia</td>
<td>Satellite Symposia</td>
<td>Satellite Symposia</td>
<td></td>
</tr>
<tr>
<td>17.00</td>
<td></td>
<td>Satellite Symposia</td>
<td>Satellite Symposia</td>
<td>Satellite Symposia</td>
<td>Satellite Symposia</td>
</tr>
<tr>
<td>17.30</td>
<td></td>
<td>Satellite Symposia</td>
<td>Satellite Symposia</td>
<td>Satellite Symposia</td>
<td>Satellite Symposia</td>
</tr>
<tr>
<td>18.30</td>
<td>Satellite Symposia</td>
<td>Satellite Symposia</td>
<td>Satellite Symposia</td>
<td>Satellite Symposia</td>
<td>Satellite Symposia</td>
</tr>
<tr>
<td>19.00</td>
<td>Opening</td>
<td>5K@IDF</td>
<td>Farewell evening</td>
<td>Farewell evening</td>
<td>Farewell evening</td>
</tr>
<tr>
<td>19.30</td>
<td></td>
<td>5K@IDF</td>
<td>Farewell evening</td>
<td>Farewell evening</td>
<td>Farewell evening</td>
</tr>
<tr>
<td>20.30</td>
<td></td>
<td>Farewell evening</td>
<td>Farewell evening</td>
<td>Farewell evening</td>
<td>Farewell evening</td>
</tr>
<tr>
<td>22.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Farewell evening</td>
</tr>
</tbody>
</table>
The Organising Committee of the IDF 2017 Congress expresses its appreciation and recognition to the following organisations for their support:

- Abu Dhabi Convention Bureau
- Abu Dhabi Department of Culture and Tourism
- Abu Dhabi Department of Health
- Abu Dhabi Department of Transport

**SATELLITE SYMPOSIA OVERVIEW**

**MONDAY 4 DECEMBER**

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Organiser</th>
<th>Theme</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30 - 14:30</td>
<td>Conference Hall A</td>
<td>Lilly Diabetes</td>
<td>The transition to injectable therapies: Navigating clinical and emotional challenges in T2DM</td>
</tr>
<tr>
<td>15:30 - 17:30</td>
<td>Conference Hall A</td>
<td>Boehringer Ingelheim</td>
<td>Improving cardiovascular outcomes in patients with type 2 diabetes: Applying new evidence in practice</td>
</tr>
<tr>
<td>15:30 - 17:30</td>
<td>Conference Hall B</td>
<td>Takeda</td>
<td>Shaping the future of type 2 diabetes management: What next?</td>
</tr>
</tbody>
</table>
### TUESDAY 5 DECEMBER

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Organization</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:45 - 12:45</td>
<td>Conference Hall B</td>
<td>Roche Diabetes Care</td>
<td><strong>Shaping the future of integrated diabetes management solutions</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>and clinical treatment for patients with type 2 diabetes</td>
</tr>
<tr>
<td>12:00 - 13:00</td>
<td>Diabetes Spotlight</td>
<td>Sanofi Pasteur</td>
<td>**Impact of influenza on people living with diabetes: A serious and</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>under-appreciated threat**</td>
</tr>
<tr>
<td>17:30 - 19:30</td>
<td>ICC 1</td>
<td>AstraZeneca</td>
<td><strong>Precision medicine for Type 2 diabetes</strong></td>
</tr>
<tr>
<td>17:30 - 19:30</td>
<td>ICC 4</td>
<td>MSD</td>
<td><strong>10 years of DPP-4 inhibition: Understanding new science and</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>clinical treatment for patients with type 2 diabetes</td>
</tr>
<tr>
<td>17:30 - 19:30</td>
<td>Conference Hall A</td>
<td>Sanofi</td>
<td>**Evolving strategies for early, effective glycemic control in Type 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>diabetes**</td>
</tr>
<tr>
<td>17:30 - 19:30</td>
<td>Conference Hall B</td>
<td>Novo Nordisk</td>
<td><strong>Next generation of ultra-long acting insulins in type 2 diabetes</strong></td>
</tr>
<tr>
<td>17:30 - 19:30</td>
<td>Capital Suite 1</td>
<td></td>
<td>**Advancing an integrated model of quality eye care, diabetes and</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NCDs**</td>
</tr>
<tr>
<td>18:30 - 20:30</td>
<td>Hall 11</td>
<td>Novo Nordisk</td>
<td>**Cardiovascular outcome trials: closing a gap in management of type 2</td>
</tr>
</tbody>
</table>
### WEDNESDAY 6 DECEMBER

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Organizer</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:45 - 12:45</td>
<td>Conference Hall B</td>
<td>Novartis</td>
</tr>
<tr>
<td>12:00 - 13:00</td>
<td><strong>Fighting clinical inertia: When and how</strong></td>
<td>Sanofi</td>
</tr>
<tr>
<td>13:30 - 14:30</td>
<td>Diabetes Spotlight</td>
<td>Dexcom/Julphar</td>
</tr>
<tr>
<td>17:30 - 19:30</td>
<td><strong>Continuous glucose monitoring (CGM): The emerging global standard of care for glucose monitoring</strong></td>
<td>Servier</td>
</tr>
<tr>
<td>17:30 - 19:30</td>
<td>Conference Hall A</td>
<td>Novo Nordisk</td>
</tr>
<tr>
<td></td>
<td><strong>The pursuit of ultra-fast insulins</strong></td>
<td></td>
</tr>
<tr>
<td>17:30 - 19:30</td>
<td>Capital Suite 1</td>
<td>D&amp;CVD EASD Study Group &amp; Forschergruppe Diabetes</td>
</tr>
<tr>
<td></td>
<td><strong>Diabetic complications: Challenges and opportunities, Hellmut Mehnert Award</strong></td>
<td></td>
</tr>
</tbody>
</table>

### THURSDAY 7 DECEMBER

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Organizer</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00-13:00</td>
<td>Diabetes Spotlight</td>
<td>Sanofi</td>
</tr>
<tr>
<td></td>
<td><strong>Fixed-ratio combinations: a practical approach to individualised care</strong></td>
<td></td>
</tr>
<tr>
<td>13:30 - 14:30</td>
<td>Diabetes Spotlight</td>
<td>International Hypoglycaemia Study Group</td>
</tr>
<tr>
<td></td>
<td><strong>Hypoglycaemia: a practical approach to a global problem</strong></td>
<td></td>
</tr>
<tr>
<td>17:30 - 19:30</td>
<td>Conference Hall B</td>
<td>Novo Nordisk</td>
</tr>
<tr>
<td></td>
<td><strong>Targeting weight and comorbidities via the GLP-1 receptor</strong></td>
<td></td>
</tr>
</tbody>
</table>
SATELLITE SYMPOSIUM

MONDAY 4 DECEMBER
**Lilly - The transition to injectable therapies: Navigating clinical and emotional challenges in T2DM**

12:30 - 14:30 Conference Hall A

**Welcome and introduction**

*Chair:* M. Hassanein (United Arab Emirates)  
*Chair:* A. Jabbar (United Arab Emirates)

12:40 **Patient Case #1: The path to insulin treatment**

*Speaker:* M. Hassanein (United Arab Emirates)  
*Speaker:* W. Polonsky (USA)

13:30 **Patient Case #2: Beyond oral therapy: GLP-1 receptor agonists as potential injectable options**

*Speaker:* F. Giorgino (Italy)

14:20 **Summary and close**

*Chair:* M. Hassanein (United Arab Emirates)  
*Chair:* A. Jabbar (United Arab Emirates)

This symposium has been partially sponsored by the Boehringer Ingelheim and Lilly Diabetes Alliance
Boehringer Ingelheim - Improving cardiovascular outcomes in patients with type 2 diabetes: Applying new evidence in practice

15:30 - 17:30 Conference Hall A

**Welcome and introduction**
Chair: S. Kahn (USA)  
Chair: A. Alsheikh-Ali (United Arab Emirates)

15:40  
**Diabetes management in the era of cardiovascular outcomes trials**  
Speaker: S. Kahn (USA)

16:00  
**Heart failure and kidney disease in type 2 diabetes: where can new evidence lead us?**  
Speaker: S. Verma (Canada)

16:30  
**Navigating the complexity of type 2 diabetes in daily clinical practice**  
Speaker: K. Khunti (United Kingdom)

16:50  
**Experience with SGLT2 inhibitors: Insights from practice**  
*All faculty*

17:20  
**Chair’s summary**  
Chair: S. Kahn (USA)

This symposium has been partially sponsored by the Boehringer Ingelheim and Lilly Diabetes Alliance
MONDAY 4 DECEMBER 2017

SATELLITE SYMPOSIUM

15:30 - 17:30 Conference Hall B

**Takeda - Shaping the future of type 2 diabetes management: What next?**

15:30
**Welcome and introduction**
Chair: G. Schernthaner (Austria)

15:40
**What’s the benefit of combination therapy: Unique value of Alogliptin/Pioglitazone**
Speaker: G. Schernthaner (Austria)

16:00
**Overview of cardiovascular outcome trials of glucose-lowering agents**
Speaker: S. Rajagopalan (USA)

16:20
**Targeting insulin resistance: Pioglitazone 10 years data review**
Speaker: S. Genovese (Italy)

16:40
**What’s the role of Alogliptin on cardiovascular benefit in T2DM: Perspective for SPEAD-A study and EXAMINE**
Speaker: R. Chilton (USA)

17:00
**Panel discussion**

17:20
**Chairman’s close**
Chair: G. Schernthaner (Austria)
SATELLITE SYMPOSIUM

TUESDAY 5 DECEMBER
Roche Diabetes Care - Shaping the future of integrated diabetes management solutions

11:45

Introduction
Chair: W. Kaplan (United Arab Emirates)
Chair: R. Hinzmann (Germany)

11:55

Using a digital platform for connecting patients and healthcare professionals
Speaker: S. Jacob (Germany)

12:10

Personalized diabetes management (PDM) in patients with insulin-treated T2D: First experiences and lessons learned out of the PDM-ProValue study program
Speaker: L. Heinemann (Germany)

12:25

Features and performance of the new Eversense® implantable CGM system
Speaker: S. Russell (USA)

12:40

Discussion and closing
Sanofi Pasteur - Impact of influenza on people living with diabetes: A serious and under-appreciated threat

12:00 - 13:00 Diabetes Spotlight

Introduction
Chair: N. Kanumilli (United Kingdom)

12:10
Addressing influenza in people living with diabetes - Why should this matter?
Speaker: M. Akçay (Turkey)

12:25
Clinical management of influenza and diabetes: Where do we stand?
Speaker: N. Kanumilli (United Kingdom)

12:40
Protecting people living with diabetes against influenza - Lessons learned from Saudi Arabia
Speaker: F. Al Slail (Saudi Arabia)

12:55
Summary and close
AstraZeneca - Precision medicine for Type 2 diabetes

17:30 - 19:30 ICC 1

17:30
Arrivals and refreshments

17:45
Introducing precision medicine in Type 2 diabetes
Chair:  K. Khunti (United Kingdom)
Chair:  J. Vora (United Kingdom)

18:00
Should we offer early, tight and durable glycaemic control to patients with Type 2 diabetes?
Speaker:  M. Hassanein (United Arab Emirates)

18:15
What else is left to learn about the non-glycaemic effects of SGLT2 inhibitors?
Speaker:  F. Giorgino (Italy)

18:30
Optimising safety in practice with SGLT2 inhibitors
Speaker:  W. Hanif (United Kingdom)

18:45
What do we need to know when choosing a first injectable in Type 2 diabetes?
Speaker:  F. Knop (Denmark)

19:00
Glucose-lowering therapies and cardiovascular mortality: Where are we now?
Speaker:  N. Sattar (United Kingdom)

19:15
Panel discussion: Bringing precision to the choice of therapy in Type 2 diabetes
Co-chairs and speakers

19:25
Summary and close
Chair:  J. Vora (United Kingdom)
17:30 - 19:30 ICC 4

**MSD - 10 years of DPP-4 inhibition: Understanding new science and clinical treatment for patients with type 2 diabetes**

17:30  
Chair welcome and opening remarks  
Chair:  S. Kahn (USA)  
Chair:  T. Fiad (United Arab Emirates)

17:35  
New science in the understanding of incretin activity at the cellular level: Is there more to learn?  
Speaker:  J. Campbell (USA)

17:50  
Q&A

17:55  
Microvascular and macrovascular complications: The importance of addressing both in our patients with type 2 diabetes  
Speaker:  C. Bailey (United Kingdom)  
Speaker:  A. Gitt (Germany)

18:25  
Where do DPP-4 inhibitors fit within today’s treatment paradigm for patients with type 2 diabetes? The latest data and implications for our patients  
Speaker:  T. Fiad (United Arab Emirates)

18:50  
Q&A

18:55  
Clinical considerations in the individualized treatment of patients with type 2 diabetes: An interactive patient case discussion  
Speaker:  S. Kahn and Faculty

19:25  
Final comments and summary
**Sanofi - Evolving strategies for early, effective glycemic control in Type 2 diabetes**

**17:30 - 19:30 Conference Hall A**

**Welcome and introduction**  
*Chair: H. Ezzeddin (United Arab Emirates)*

**Innovations in basal insulin: insights from the real world**

**17:35**  
*Looking across the evidence spectrum: from RCT to RWE*  
*Speaker: N. Freemantle (United Kingdom)*

**17:45**  
*Need for earlier insulin initiation and continuous titration*  
*Speaker: D. Mauricio (Spain)*

**18:00**  
*Basal insulin therapy with Gla-300: evidence from the real world*  
*Speaker: A. Cheng (Canada)*

**Fixed-ratio combination therapy: a new approach to T2DM management**

**18:20**  
*Simultaneous vs. stepwise: the rationale for early combination therapy*  
*Speaker: J.P. Frías (USA)*

**18:30**  
*Fixed-ratio combination therapy for early, effective control: the LixiLan-O and -L studies*  
*Speaker: P. Mora (USA)*

**18:45**  
*A closer look at fixed-ratio combination therapy*  
*Speaker: J.P. Frías (USA)*

**Panel discussion**

**19:05**  
*Breaking through the barriers to effective glycemic control*  
*Faculty and Raconteur Lori Berard*

**19:25**  
*Closing remarks*  
*Chair: H. Ezzeddin (United Arab Emirates)*
Novo Nordisk - Next generation of ultra-long acting insulins in type 2 diabetes

Chair: A. Ceriello (Italy)

17:30
The evolution of insulin therapy
Speaker: A. Ceriello (Italy)

17:45
Starting point: The mode of action of next generation insulins
Speaker: L. Landstedt-Hallin (Sweden)

18:05
Evidence of reducing hypoglycemia risk with ultra-long acting insulin
Speaker: S. Atkin (Qatar)

18:30
Changing the insulin intensification paradigm
Speaker: R. Mehta (Mexico)

18:55
Insulin treatment before, during and after Ramadan
Speaker: M. Hassanein (United Arab Emirates)

19:15
Q&A

19:25
Summary and closing remarks
Chair: A. Ceriello (Italy)
17:30 - 19:30 Capital Suite 1

**Advancing an integrated model of quality eye care, diabetes and NCDs**

**Chair:** J. Brumby (Australia)
**Chair:** N. Cho (Korea)

17:40 **Introduction**
**Chair:** J. Brumby (Australia)

17:45 **Diabetes, eye health and NCD care: The case for integration**
**Speaker:** W. Mathenge (Rwanda)

18:15 **Case study: Integrated models of care for DR in India**
**Speaker:** G.V.S. Murthy (India)

18:30 **Case study: Integrated models for DR care in China**
**Speaker:** N. Congdon (USA)
**Speaker:** N. Fong (China)

18:45 **Case study: Comprehensive model of eye care for vulnerable populations in the Occupied Palestinian Territory**
**Speaker:** N. Mikki (Palestine)

19:00 **Q&A**
Novo Nordisk - Cardiovascular outcome trials: closing a gap in management of type 2 diabetes?

18:30
Welcome and introduction
Chair: E. Montanya (Spain)

18:35
Cardiovascular risk management in type 2 diabetes: where are we in 2017?
Speaker: L. Mellbin (Sweden)

18:55
Cardiovascular outcome trials in type 2 diabetes: a paradigm shift?
Speaker: J. Deanfield (United Kingdom)

19:15
Long-term clinical and metabolic outcomes with GLP-1 receptor agonists
Speaker: J. Mann (Germany)

19:35
GLP-1 receptor agonists and the cardiovascular system: effects beyond glycaemia
Speaker: F. Knop (Denmark)

19:55
Bridging trial results to patient care: two perspectives
Speaker: R. Réa (Brazil)
Speaker: J. Deanfield (United Kingdom)

20:10
Panel discussion

20:25
Meeting close
Chair: E. Montanya (Spain)
SATELLITE SYMPOSIUM

WEDNESDAY 6 DECEMBER
Novartis - Fighting Clinical Inertia: When and how

11:45  Welcome & introduction
      Chair: I. Ksseiry (United Arab Emirate)

11:50  Clinical inertia and how to overcome barriers to early treatment intensification
      Speaker: J. Chan (Chin)

12:10  Addressing clinical inertia in type 2 diabetes
      Speaker: D. Strain (United Kingdom)

12:30  Q&A
**Sanofi - Let’s talk about basal insulin: taking a three-dimensional approach**

12:00  Welcome and introduction  
*Chair:  A. Cheng (Canada)*

12:05  Basal insulin: an essential dialogue between evidence and clinical practice  
*Speaker:  A. Cheng (Canada)*  
*Speaker:  A. Philis-Tsimikas (USA)*

12:30  Characteristics and patterns of care for diabetes patients during Ramadan – a prospective study  
*Speaker:  M. Hassanein (United Arab Emirates)*

12:50  Q&A and closing remarks  
*Chair:  A. Philis-Tsimikas (USA)*
13:30 - 14:30 Diabetes Spotlight

Dexcom/Julphar - Continuous glucose monitoring (CGM): The emerging global standard of care for glucose monitoring

Chair: A. Al Madani (United Arab Emirates)

13:30

A practical and clinical application of continuous glucose monitoring (CGM) with intensive insulin requiring patients

Speaker: S. Adi (USA)

Speaker: L. Krinelke (Switzerland)
Servier - Tackling unmet needs in type 2 diabetes: Evolving perspectives

Chair: A. Al Madani (United Arab Emirates)
Chair: R. Henry (USA)

17:30
Introduction
Speaker: A. Al Madani (United Arab Emirates)

17:35
Achieving better glycemic control: Unmet needs and main barriers
Speaker: K. Khunti (United Kingdom)

17:55
How does adherence impact treatment success?
Speaker: F. Snoek (The Netherlands)

18:15
A novel approach to improving adherence and patient outcomes in T2D
Speaker: R. Henry (USA)

18:45
Panel discussion

19:05
Conclusion
Speaker: R. Henry (USA)
Novo Nordisk - The pursuit of ultra-fast insulins

17:30 Welcome and introduction  
Chair: S.L. Atkin (Qatar)

17:40 Pharmacological performance of faster aspart  
Speaker: T. Heise (Germany)

18:05 Physiological effect of faster aspart on endogenous glucose production  
Speaker: T. Pieber (Austria)

18:30 on set programme: from clinical pharmacology to clinical benefits in type 1 and type 2 diabetes  
Speaker: V. Woo (Canada)
Speaker: H.W. Rodbard (USA)

19:00 Panel discussion

19:25 Meeting close  
Chair: S.L. Atkin (Qatar)
**D&CVD EASD Study Group & Forschergruppe Diabetes - Diabetic complications: Challenges and opportunities, Hellmut Mehnert Award**

**Hellmut Mehnert Award**

17:30  
**Introduction to the award**  
*Chair:*  R. Holman  (*United Kingdom*)

17:40  
**Video message by Hellmut Mehnert**

17:45  
**Laudation and presentation of awardee**  
*Chair:*  R. Holman  (*United Kingdom*)

17:50  
**Lecture of awardee: The renaissance of glycaemology**  
*Speaker:*  A. Ceriello  (*Italy*)

**Diabetic complications: Challenges and opportunities**

*Chair:*  O. Schnell  (*Germany*)

18:30  
**ACE-Trial: Results and implications**  
*Speaker:*  E. Standl  (*Germany*)

18:55  
**Diabetes and heart failure: From unexpected results to treatment targets**  
*Speaker:*  I. Raz  (*Israel*)

19:25  
**Summary and close**  
*Chair:*  R. Holman  (*United Kingdom*)  
*Chair:*  O. Schnell  (*Germany*)
SATELLITE SYMPOSIUM

THURSDAY 7 DECEMBER
12:00 - 13:00 Diabetes Spotlight

**Sanofi - Fixed-ratio combinations: a practical approach to individualised care**

12:00  **Welcome and introduction**  
*Chair:  L. Berard (Canada)*

12:05  **Individualizing care through titratable fixed-ratio combination treatment approaches**  
*Speaker:  J.P. Frías (USA)*

12:25  **Case study: combination therapy in the clinic**  
*Speaker:  P. Mora (USA)*

12:45  **Q&A**  
*All*

12:55  **Closing remarks**  
*Chair:  L. Berard (Canada)*
13:30 - 14:30 Diabetes Spotlight

International Hypoglycaemia Study Group - Hypoglycaemia: a practical approach to a global problem

13:30 Introduction
Speaker: S. Heller (United Kingdom)

13:35 Global prevalence and impact
Speaker: K. Khunti (United Kingdom)

13:45 Prevention and treatment
Speaker: B. Frier (United Kingdom)

13:55 Classification and clinical implications
Speaker: S. Zoungas (Australia)

14:05 Panel discussion
Novo Nordisk - Targeting weight and comorbidities via the GLP-1 receptor

17:30  Welcome and introduction
      Chair: S. Taheri (Qatar)

17:40  Why should we treat obesity?
      Speaker: D. Ryan (USA)

18:05  Hormonal adaptations to weight loss
      Speaker: J. Proietto (Australia)

18:25  Targeting weight and comorbidities via the GLP-1 receptor
      Speaker: C. le Roux (Ireland)

19:05  Panel discussion

19:25  Meeting close
      Chair: S. Taheri (Qatar)